Adaptive Biotechnologies

General Information
Business:

 

We are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 346
Founded: 2009
Contact Information
Address 1551 Eastlake Avenue East, Suite 200, Seattle, Washington 98102, US
Phone Number (206) 659-0067
Web Address http://www.adaptivebiotech.com
View Prospectus: Adaptive Biotechnologies
Financial Information
Market Cap $1895.6mil
Revenues $58.6 mil (last 12 months)
Net Income $-52.6 mil (last 12 months)
IPO Profile
Symbol ADPT
Exchange NASDAQ
Shares (millions): 12.5
Price range $15.00 - $17.00
Est. $ Volume $200.0 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch
CO-Managers Cowen/ Guggenheim Securities/ William Blair/ BTIG
Expected To Trade: 6/27/2019
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change